Market Research Logo

Neuromodulation Devices Global Market – Forecast To 2026

Neuromodulation Devices Global Market – Forecast To 2026

Neuromodulation treatment involves direct stimulation or modulation of the nerves by an electrical or magnetic field. It is used as a treatment for unmanageable chronic pain, movement disorders, gastroenterology, urology and others. The treatment delivered by neuromodulation devices brings about life-changing transformation in patients who fail to get better by traditional approaches. This therapy is based on the natural process of stimulation of nerve cell activity and release of neurotransmitters that regulate nerve activity. Neuromodulation is gaining popularity because these devices have been very successful in the treatment of conditions for which medicines have failed completely or may have unpleasant side effects.

An estimated by IQ4I Research, the neuromodulation devices global market is expected to reach $9,917.0 million by 2026 growing at high single digit CAGR from 2019 to 2026 due to increasing incidence of chronic pain, increasing Parkinson’s and Alzheimer’s disorders, low approval rate of CNS drugs, favorable reimbursement scenario in major markets, the emergence of neuromodulation as add-on therapy, technological innovations, rise in the number of clinical studies performed and expansion in emerging markets. The neuromodulation devices market is segmented by product, application, end-user, and geography.

Based on the product the neuromodulation global market is segmented into internal neuromodulation and external neuromodulation devices. Internal neuromodulation devices segment accounted for the largest revenue in 2019 and is expected to grow at a high single digit CAGR from 2019 to 2026. Internal neuromodulation devices market is segmented into spinal cord stimulator (SCS), deep brain stimulator (DBS), sacral nerve stimulator (SNS), vagus nerve stimulator (VNS) and others. Among internal neuromodulation devices, Spinal cord stimulator (SCS) segment accounted for the largest revenue in 2019 and is expected to grow at a double digit CAGR from 2019 to 2026 due to increase in the incidence of chronic pain, increase in movement disorders and high implantation rate of spinal cord stimulators. The external neuromodulation devices market is segmented into transcutaneous electrical nerve stimulator (TENS), neuromuscular electrical stimulator (NMES) and others. Among external neuromodulation devices, transcutaneous electrical nerve stimulation (TENS) segment accounted for the largest revenue in 2019 and is expected to grow at a low single digit CAGR from 2019 to 2026.

Based on the application, the neuromodulation devices global market is segmented into pain management, central nervous system, gastroenterology and urology, and other disorders (respiratory, Sleep Apnea, obesity and diabetic neuropathy). Among application, pain management segment accounted for the largest revenue in 2019 and is expected to grow at a high single digit CAGR from 2019 to 2026. Pain management is further segmented into chronic pain, failed back surgery syndrome, and others (migraine, and ischemia). Among pain management, chronic pain segment accounted for the largest revenue in 2019 and is expected to grow at a high single digit CAGR from 2019 to 2026 due to increasing incidence of chronic pain, increasing utilizing of the spinal cord stimulators, and advancement in neuromodulation devices.

Central nervous system is further segmented into Parkinson’s disorders, essential tremor, dystonia, epilepsy, depression, and others (Obsessive-compulsive disorder (OCD) and anxiety). Among Central nervous system disorders, Epilepsy segment accounted for the largest revenue in 2019 and is expected to grow at a high single digit CAGR from 2019 to 2026. Gastroenterology and Urology is further segmented into gastroparesis, urinary incontinence, and fecal incontinence. Among Gastroenterology and Urology urinary incontinence segment accounted for the largest revenue in 2019 and is expected to grow at a mid-single digit CAGR from 2019 to 2026.

Based on the end-user, the neuromodulation devices global market is segmented into hospitals and ambulatory surgery centers, clinics and physiotherapy centers and Academics and research. Among end-user, Hospitals and ambulatory surgery centers accounted for the largest revenue in 2019 and is expected to grow at a high single digit CAGR from 2019 to 2026.

Based on the region, the neuromodulation devices global market is segmented into North America (U.S. and Rest of North America), Europe (Germany, France, U.K and Rest of Europe), Asia-Pacific (Japan, China, India, and Rest of APAC) and Rest of the world (Brazil, Rest of Latin America and Middle East & others). North America accounted for the largest revenue in 2019 and is expected to grow at a high single digit CAGR from 2019 to 2026 due to high technological advancements, increased growing awareness about medical care, treatment style, increase in the aging population, strong product pipeline, new indications, investments and funds, increases in neurological diseases, sophisticated infrastructure related to healthcare and high expenditure present among the population of North America are boosting the market of neuromodulation devices.

The Asia-Pacific is the fastest growing region with a double digit CAGR from 2019 to 2026 due to rising incidences of neurological disorders, government initiatives to increasing awareness by education campaigns, large pool of patients, increasing geriatric population, advancements in surgeries and technologies, increased healthcare facilities, increasing adoption of implantable devices, high acceptance of technological advancements, the easy availability of advanced healthcare technology, skilled personnel and low-cost for the surgery are driving the market.

The neuromodulation devices global market is a highly consolidated market hence all the existing players in this market are involved in developing new and advanced technologies to maintain their market shares. Some of the major players in Neuromodulation devices market include Medtronic Plc (Ireland), Abbott Laboratories (U.S.), Boston Scientific Corporation (U.S.), LivaNova Plc (U.K.), Nevro Corporation (U.S.), Inspire Medical System, Inc. (U.S.), Nuvectra (U.S.), Neuropace Inc. (U.S.), Bioness Inc. (U.S.), Beijing PINS Medical Co., Ltd. (China), Laborie Medical (Canada) and Neuronetics, Inc. (U.S.).

The report provides an in-depth market analysis of the above-mentioned segments across the following regions:

  • North America
  • U.S.
  • Rest of North America
  • Europe
  • Germany
  • France
  • U.K.
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Rest of APAC
  • Rest of the World (RoW)
  • Brazil
  • Rest of Latin America
  • Middle East and Others


1 EXECUTIVE SUMMARY
2 INTRODUCTION
2.1 KEY TAKEAWAYS
2.2 SCOPE OF THE REPORT
2.3 REPORT DESCRIPTION
2.4 MARKETS COVERED
2.5 STAKEHOLDERS
2.6 RESEARCH METHODOLOGY
2.6.1 MARKET SIZE ESTIMATION
2.6.2 MARKET BREAKDOWN AND DATA TRIANGULATION
2.6.3 SECONDARY SOURCES
2.6.4 PRIMARY SOURCES
2.6.5 KEY DATA POINTS FROM SECONDARY SOURCES
2.6.6 KEY DATA POINTS FROM PRIMARY SOURCES
2.6.7 ASSUMPTIONS
3 MARKET ANALYSIS
3.1 INTRODUCTION
3.2 MARKET SEGMENTATION
3.3 FACTORS INFLUENCING MARKET
3.3.1 DRIVERS AND OPPORTUNITIES
3.3.1.1 Increasing incidence of chronic pain
3.3.1.2 Increasing parkinson’s and alzheimer’s disorder’s
3.3.1.3 Low approval rate of CNS drugs is driving neuromodulation market
3.3.1.4 Favorable reimbursement scenario in major markets
3.3.1.5 The emergence of neuromodulation as add on therapy
3.3.1.6 Technological innovations in neuromodulation
3.3.1.7 Expansion in emerging markets
3.3.1.8 The rise in the number of clinical studies performed
3.3.2 RESTRAINTS AND THREATS
3.3.2.1 Side effects and risks associated with the use
3.3.2.2 Lack of trained professionals
3.3.2.3 Availability of alternative treatments
3.3.2.4 Stringent regulatory guidelines
3.4 REGULATORY AFFAIRS
3.4.1 INTERNATIONAL ORGANIZATION FOR STANDARDIZATION
3.4.1.1 ISO 9001: 2015 Quality management system
3.4.1.2 ISO 13485 Medical devices
3.4.1.3 ISO 10993 Biological evaluation of medical devices
3.4.2 U.S.
3.4.3 CANADA
3.4.4 EUROPE
3.4.5 JAPAN
3.4.6 CHINA
3.4.7 INDIA
3.5 CLINICAL TRIALS DATA
3.6 TECHNOLOGICAL ADVANCEMENTS
3.6.1 RECHARGEABLE SYSTEMS
3.6.2 OPTOGENETIC TECHNOLOGY
3.6.3 FOCUSED ULTRASOUND (FUS)
3.6.4 MINIATURIZATION
3.6.5 PORTABLE NUEROMODULATION SYSTEMS (PONS)
3.6.6 WEARABLE PAIN MANAGEMENT TECHNOLOGY
3.6.7 TRANS-SPINAL DIRECT CURRENT STIMULATION (TSDCS)
3.6.8 NANO-NEUROMODULATION
3.6.9 BIOACTIVE COATINGS
3.7 PORTER’S FIVE FORCE ANALYSIS
3.7.1 THREAT OF NEW ENTRANTS
3.7.2 THREAT OF SUBSTITUTES
3.7.3 BARGAINING POWER OF SUPPLIERS
3.7.4 BARGAINING POWER OF BUYERS
3.7.5 COMPETITIVE RIVALRY
3.8 SUPPLY CHAIN ANALYSIS
3.9 REIMBURSEMENT SCENARIO
3.9.1 REIMBURSEMENT TABLE
3.10 REGULATORY APPROVED NEUROMODULATION DEVICES
3.10.1 SPINAL CORD STIMULATORS (SCS)
3.10.2 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATOR (TENS)
3.10.3 DEEP BRAIN STIMULATION (DBS)
3.10.4 SACRAL NERVE STIMULATION (SNS)
3.10.5 VAGUS NERVE STIMULATION (VNS)
3.10.6 TRANSCRANIAL MAGNETIC STIMULATION (TMS)
3.11 FUNDING SCENARIO
3.12 MARKET SHARE ANALYSIS BY MAJOR PLAYERS
3.12.1 NEUROMODULATION DEVICES GLOBAL MARKET SHARE ANALYSIS
3.12.2 SPINAL CORD STIMULATORS GLOBAL MARKET SHARE ANALYSIS
3.12.3 DEEP BRAIN STIMULATORS GLOBAL MARKET SHARE ANALYSIS
3.13 NEUROMODULATION DEVICES NUMBER OF UNITS BY REGION
3.13.1 SPINAL CORD STIMULATION (SCS) NUMBER OF UNITS BY REGION
3.13.2 DEEP BRAIN STIMULATION (DBS) NUMBER OF UNITS BY REGION
3.13.3 SACRAL NERVE STIMULATION (SNS) NUMBER OF UNITS BY REGION
3.13.4 VAGUS NERVE STIMULATION (VNS) NUMBER OF UNITS BY REGION
3.13.5 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS)
NUMBER OF UNITS BY REGION
3.13.6 NEUROMUSCULAR ELECTRICAL STIMULATION (NMES)
NUMBER OF UNITS BY REGION
3.14 MARKET PENETRATION
3.15 NEUROMODULATION DEVICES COMPANY COMPARISON TABLE BY REVENUE, TECHNOLOGY, PRODUCTS AND APPLICATION
4 NEUROMODULATION DEVICES GLOBAL MARKET, BY PRODUCT
4.1 INTRODUCTION
4.2 INTERNAL NEUROMODULATION DEVICES
4.2.1 SPINAL CORD STIMULATION (SCS)
4.2.2 DEEP BRAIN STIMULATION (DBS)
4.2.3 SACRAL NERVE STIMULATION (SNS)
4.2.4 VAGUS NERVE STIMULATION (VNS)
4.2.5 OTHER INTERNAL NEUROMODULATION DEVICES
4.2.5.1 Gastric electric stimulation (GES)
4.2.5.2 Respiratory electrical stimulation (RES)/
Phrenic nerve stimulation (PNS)
4.2.5.3 Hypoglossal nerve stimulation (HGNS)
4.3 EXTERNAL NEUROMODULATION DEVICES
4.3.1 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS)
4.3.2 NEUROMUSCULAR ELECTRICAL STIMULATION (NMES)
4.3.3 OTHER EXTERNAL NEUROMODULATION DEVICES
4.3.3.1 Transcranial magnetic stimulation (TMS)
4.3.3.2 Functional electrical stimulation (FES)
4.3.3.3 Electro conclusive therapy (ECT)
4.3.3.4 Percutaneous tibial nerve stimulation (PTNS)
4.3.3.5 Portable neuromodulation stimulator (PONS)
4.3.3.6 Transcranial direct current stimulation (TDCS)
4.3.3.7 Transcranial alternating current stimulation (TACS)
4.3.3.8 Trigeminal nerve stimulation (TNS)
5 NEUROMODULATION DEVICES GLOBAL MARKET, BY APPLICATION
5.1 INTRODUCTION
5.2 PAIN MANAGEMENT
5.2.1 CHRONIC PAIN
5.2.2 FAILED BACK SURGERY SYNDROME (FBSS)
5.2.3 OTHER PAIN MANAGEMENT
5.3 CENTRAL NERVOUS SYSTEM (CNS)
5.3.1 PARKINSON'S DISEASE
5.3.2 ESSENTIAL TREMORS
5.3.3 DYSTONIA
5.3.4 EPILEPSY
5.3.5 DEPRESSION
5.3.6 OTHER CNS
5.4 GASTROENTEROLOGY AND UROLOGY
5.4.1 GASTROPARESIS
5.4.2 URINARY INCONTINENCE
5.4.3 FAECAL INCONTINENCE
5.5 OTHER APPLICATIONS
6 NEUROMODULATION DEVICES GLOBAL MARKET, BY END-USERS
6.1 INTRODUCTION
6.2 HOSPITALS AND AMBULATORY SURGERY CENTERS (ASC)
6.3 CLINICS AND PHYSIOTHERAPY CENTERS
6.4 ACADEMICS AND RESEARCH
7 REGIONAL ANALYSIS
7.1 INTRODUCTION
7.2 NORTH AMERICA
7.2.1 U.S.
7.2.2 REST OF NORTH AMERICA
7.3 EUROPE
7.3.1 GERMANY
7.3.2 FRANCE
7.3.3 U.K.
7.3.4 REST OF EUROPE
7.4 APAC
7.4.1 JAPAN
7.4.2 CHINA
7.4.3 INDIA
7.4.4 REST OF APAC
7.5 ROW
7.5.1 BRAZIL
7.5.2 REST OF LATAM
7.5.3 MIDDLE EAST AND OTHERS
8 COMPETITIVE LANDSCAPE
8.1 INTRODUCTION
8.2 PRODUCT APPROVAL
8.3 NEW PRODUCT LAUNCH
8.4 AGREEMENTS AND PARTNERSHIPS
8.5 OTHERS
9 MAJOR COMPANIES
9.1 ABBOTT LABORATORIES
9.1.1 OVERVIEW
9.1.2 FINANCIALS
9.1.3 PRODUCT PORTFOLIO
9.1.4 KEY DEVELOPMENTS
9.1.5 BUSINESS STRATEGY
9.1.6 SWOT ANALYSIS
9.2 BEIJING PINS MEDICAL CO., LTD.
9.2.1 OVERVIEW
9.2.2 FINANCIALS
9.2.3 PRODUCT PORTFOLIO
9.2.4 KEY DEVELOPMENTS
9.2.5 BUSINESS STRATEGY
9.2.6 SWOT ANALYSIS
9.3 BIONESS, INC.
9.3.1 OVERVIEW
9.3.2 FINANCIALS
9.3.3 PRODUCT PORTFOLIO
9.3.4 KEY DEVELOPMENTS
9.3.5 BUSINESS STRATEGY
9.3.6 SWOT ANALYSIS
9.4 BOSTON SCIENTIFIC CORPOARTION
9.4.1 OVERVIEW
9.4.2 FINANCIALS
9.4.3 PRODUCT PORTFOLIO
9.4.4 KEY DEVELOPMENTS
9.4.5 BUSINESS STRATEGY
9.4.6 SWOT ANALYSIS
9.5 INSPIRE MEDICAL SYSTEM, INC.
9.5.1 OVERVIEW
9.5.2 FINANCIALS
9.5.3 PRODUCT PORTFOLIO
9.5.4 KEY DEVELOPMENTS
9.5.5 BUSINESS STRATEGY
9.5.6 SWOT ANALYSIS
9.6 LABORIE MEDICAL TECHNOLOGIES, INC. (COGENTIX MEDICAL)
9.6.1 OVERVIEW
9.6.2 FINANCIALS
9.6.3 PRODUCT PORTFOLIO
9.6.4 KEY DEVELOPMENTS
9.6.5 BUSINESS STRATEGY
9.6.6 SWOT ANALYSIS
9.7 LIVANOV PLC (SORIN GROUP)
9.7.1 OVERVIEW
9.7.2 FINANCIALS
9.7.3 PRODUCT PORTFOLIO
9.7.4 KEY DEVELOPMENTS
9.7.5 BUSINESS STRATEGY
9.7.6 SWOT ANALYSIS
9.8 MEDTRONIC PLC
9.8.1 OVERVIEW
9.8.2 FINANCIALS
9.8.3 PRODUCT PORTFOLIO
9.8.4 KEY DEVELOPMENTS
9.8.5 BUSINESS STRATEGY
9.8.6 SWOT ANALYSIS
9.9 NEVRO CORPOARTION
9.9.1 OVERVIEW
9.9.2 FINANCIALS
9.9.3 PRODUCT PORTFOLIO
9.9.4 KEY DEVELOPMENTS
9.9.5 BUSINESS STRATEGY
9.9.6 SWOT ANALYSIS
9.10 NEUROPACE, INC.
9.10.1 OVERVIEW
9.10.2 FINANCIALS
9.10.3 PRODUCT PORTFOLIO
9.10.4 KEY DEVELOPMENTS
9.10.5 BUSINESS STRATEGY
9.10.6 SWOT ANALYSIS
9.11 NUVECTRA CORPORATION
9.11.1 OVERVIEW
9.11.2 FINANCIALS
9.11.3 PRODUCT PORTFOLIO
9.11.4 KEY DEVELOPMENTS
9.11.5 BUSINESS STRATEGY
9.11.6 SWOT ANALYSIS
LIST OF TABLES
TABLE 1 NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
TABLE 2 SCS NUMBER OF UNITS, BY REGION, (2018-2026) (NO’S)
TABLE 3 DBS NUMBER OF UNITS, BY REGION, (2018-2026) (NO’S)
TABLE 4 SNS NUMBER OF UNITS, BY REGION, (2018-2026) (NO’S)
TABLE 5 VNS NUMBER OF UNITS, BY REGION, (2018-2026) (NO’S)
TABLE 6 TENS NUMBER OF UNITS, BY REGION, (2018-2026) (NO’S)
TABLE 7 NMES NUMBER OF UNITS, BY REGION, (2018-2026) (NO’S)
TABLE 8 NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BY PRODUCT, (2018-2026) ($MN)
TABLE 9 NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
TABLE 10 INTERNAL NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2018-2026) ($MN)
TABLE 11 INTERNAL NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
TABLE 12 SPINAL CORD STIMULATION (SCS) GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
TABLE 13 DEEP BRAIN STIMULATION (DBS) GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
TABLE 14 SACRAL NERVE STIMULATION (SNS) GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
TABLE 15 VAGUS NERVE STIMULATION (VNS) GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
TABLE 16 OTHER INTERNAL NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
TABLE 17 EXTERNAL NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BY PRODUCT TYPE, (2018-2026) ($MN)
TABLE 18 EXTERNAL NEUROMODULATION DEVICESGLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
TABLE 19 TRANSCUTANEOUS ELECTRICAL NERVE STIMULATION (TENS) GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
TABLE 20 NEUROMUSCULAR ELECTRICAL STIMULATION (NMES) GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
TABLE 21 OTHER EXTERNAL NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
TABLE 22 NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BY APPLICATION, (2018-2026) ($MN)
TABLE 23 PAIN MANAGEMENT GLOBAL MARKET REVENUE, BY APPLICATION TYPE, (2018-2026) ($MN)
TABLE 24 PAIN MANAGEMENT GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
TABLE 25 CHRONIC PAIN GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
TABLE 26 FAILED BACK SURGERY SYNDROME (FBSS) GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
TABLE 27 OTHER PAIN MANAGEMENT GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
TABLE 28 CENTRAL NERVOUS SYSTEM (CNS) GLOBAL MARKET REVENUE, BY APPLICATION TYPE, (2018-2026) ($MN)
TABLE 29 CENTRAL NERVOUS SYSTEM (CNS) GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
TABLE 30 PARKINSON'S DISEASE GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
TABLE 31 ESSENTIAL TREMORS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
TABLE 32 DYSTONIA GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
TABLE 33 EPILEPSY GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
TABLE 34 DEPRESSION GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
TABLE 35 OTHERS GLOBAL MARKET REVENUE,VBY REGION, (2018-2026) ($MN)
TABLE 36 GASTROENTEROLOGY AND UROLOGY GLOBAL MARKET REVENUE, BY APPLICATION TYPE, (2018-2026) ($MN)
TABLE 37 GASTROENTEROLOGY AND UROLOGY GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
TABLE 38 GASTROPARESIS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
TABLE 39 URINARY INCONTINENCE GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
TABLE 40 FAECAL INCONTINENCE GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
TABLE 41 OTHER APPLICATIONS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
TABLE 42 NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BY END-USERS, (2018-2026) ($MN)
TABLE 43 HOSPITALS AND AMBULATORY SURGERY CENTERS (ASC) GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
TABLE 44 CLINICS AND PHYSIOTHERAPY CENTERS GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
TABLE 45 ACADEMICS AND RESEARCH GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
TABLE 46 NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BY REGION, (2018-2026) ($MN)
TABLE 47 NORTH AMERICA NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT, (2018-2026) ($MN)
TABLE 48 NORTH AMERICA INTERNAL NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2018-2026) ($MN)
TABLE 49 NORTH AMERICA EXTERNAL NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2018-2026) ($MN)
TABLE 50 NORTH AMERICA NEUROMODULATION DEVICES MARKET REVENUE, BY APPLICATION, (2018-2026) ($MN)
TABLE 51 NORTH AMERICA PAIN MANAGEMENT MARKET REVENUE, BY APPLICATION TYPE, (2018-2026) ($MN)
TABLE 52 NORTH AMERICA CENTRAL NERVOUS SYSTEM MARKET REVENUE, BY APPLICATION TYPE, (2018-2026) ($MN)
TABLE 53 NORTH AMERICA GASTROENTEROLOGY AND UROLOGY MARKET REVENUE, BY APPLICATION TYPE, (2018-2026) ($MN)
TABLE 54 NORTH AMERICA NEUROMODULATION DEVICES MARKET REVENUE, BY END-USERS, (2018-2026) ($MN)
TABLE 55 NORTH AMERICA NEUROMODULATION DEVICES MARKET REVENUE, BY COUNTRY, (2018-2026) ($MN)
TABLE 56 EUROPE NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT, (2018-2026) ($MN)
TABLE 57 EUROPE INTERNAL NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2018-2026) ($MN)
TABLE 58 EUROPE EXTERNAL NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2018-2026) ($MN)
TABLE 59 EUROPE NEUROMODULATION MARKET REVENUE, BY APPLICATION, (2018-2026) ($MN)
TABLE 60 EUROPE PAIN MANAGEMENT MARKET REVENUE, BY APPLICATION TYPE, (2018-2026) ($MN)
TABLE 61 EUROPE CENTRAL NERVOUS SYSTEM MARKET REVENUE, BY APPLICATION TYPE, (2018-2026) ($MN)
TABLE 62 EUROPE GASTROENTEROLOGY AND UROLOGY MARKET REVENUE, BY APPLICATION TYPE, (2018-2026) ($MN)
TABLE 63 EUROPE NEUROMODULATION DEVICES MARKET REVENUE, BY END-USERS, (2018-2026) ($MN)
TABLE 64 EUROPE NEUROMODULATION DEVICES MARKET REVENUE, BY COUNTRY, (2018-2026) ($MN)
TABLE 65 APAC NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT, (2018-2026) ($MN)
TABLE 66 APAC INTERNAL NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2018-2026) ($MN)
TABLE 67 APAC EXTERNAL NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2018-2026) ($MN)
TABLE 68 APAC NEUROMODULATION DEVICES MARKET REVENUE, BY APPLICATION, (2018-2026) ($MN)
TABLE 69 APAC PAIN MANAGEMENT MARKET REVENUE, BY APPLICATION TYPE, (2018-2026) ($MN)
TABLE 70 APAC CENTRAL NERVOUS SYSTEM MARKET REVENUE, BY APPLICATION TYPE, (2018-2026) ($MN)
TABLE 71 APAC GASTROENTEROLOGY AND UROLOGY MARKET REVENUE, BY APPLICATION TYPE, (2018-2026) ($MN)
TABLE 72 APAC NEUROMODULATION DEVICES MARKET REVENUE, BY END-USERS, (2018-2026) ($MN)
TABLE 73 APAC NEUROMODULATION DEVICES MARKET REVENUE, BY COUNTRY, (2018-2026) ($MN)
TABLE 74 ROW NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT, (2018-2026) ($MN)
TABLE 75 ROW INTERNAL NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2018-2026) ($MN)
TABLE 76 ROW EXTERNAL NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT TYPE, (2018-2026) ($MN)
TABLE 77 ROW NEUROMODULATION MARKET REVENUE, BY APPLICATION, (2018-2026) ($MN)
TABLE 78 ROW PAIN MANAGEMENT MARKET REVENUE, BY APPLICATION TYPE, (2018-2026) ($MN)
TABLE 79 ROW CENTRAL NERVOUS SYSTEM MARKET REVENUE, BY APPLICATION TYPE, (2018-2026) ($MN)
TABLE 80 ROW GASTROENTEROLOGY AND UROLOGY MARKET REVENUE, BY APPLICATION TYPE, (2018-2026) ($MN)
TABLE 81 ROW NEUROMODULATION DEVICES MARKET REVENUE, BY END-USERS, (2018-2026) ($MN)
TABLE 82 ROW NEUROMODULATION DEVICES MARKET REVENUE, BY COUNTRY, (2018-2026) ($MN)
TABLE 83 PRODUCT APPROVAL (2017-2019)
TABLE 84 NEW PRODUCT LAUNCH (2017-2019)
TABLE 85 AGREEMENTS AND PARTNERSHIPS (2017-2019)
TABLE 86 OTHERS (2017-2019)
TABLE 87 ABBOTT LABORATORIES : TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
TABLE 88 ABBOTT LABORATORIES: TOTAL REVENUE, BY SEGMENT, (2017-2019) ($MN)
TABLE 89 ABBOTT LABORATORIES: CARDIOVASCULAR AND NEUROMODULATION, BY SUB-SEGMENT, (2017-2019) ($MN)
TABLE 90 ABBOTT LABORATORIES: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
TABLE 91 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
TABLE 92 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BY SEGMENT, (2017-2019) ($MN)
TABLE 93 BOSTON SCIENTIFIC CORPORATION: RHYTHM AND NEURO, BY SUB-SEGMENT (2017-2019) ($MN)
TABLE 94 BOSTON SCIENTIFIC CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
TABLE 95 INSPIRE MEDICAL SYSTEM, INC: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
TABLE 96 INSPIRE MEDICAL SYSTEM,INC: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
TABLE 97 LIVANOVA PLC: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
TABLE 98 LIVANOVA PLC: TOTAL REVENUE, BY SEGMENT, (2017-2019) ($MN)
TABLE 99 LIVANOVA PLC: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
TABLE 100 MEDTRONIC, PLC: TOTAL REVENUE AND R&D EXPENSES, (2016-2018) ($MN)
TABLE 101 MEDTRONIC, PLC: TOTAL REVENUE, BY SEGMENT, (2016-2018) ($MN)
TABLE 102 MEDTRONIC, PLC: RESTORATIVE THERAPIES GROUP, BY SUB-SEGMENT (2016-2018) ($MN)
TABLE 103 MEDTRONIC, PLC: TOTAL REVENUE, BY GEOGRAPHY, (2016-2018) ($MN)
TABLE 104 NEVRO CORPORATION: TOTAL REVENUE AND R&D EXPENSES (2017-2019) ($MN)
TABLE 105 NEVRO CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
TABLE 106 NUVECTRA CORPORATION: TOTAL REVENUE AND R&D EXPENSES, (2017-2019) ($MN)
TABLE 107 NUVECTRA CORPORATION: TOTAL REVENUE, BY SEGMENT, (2017-2019) ($MN)
TABLE 108 NUVECTRA CORPORATION: TOTAL REVENUE, BY GEOGRAPHY, (2017-2019) ($MN)
LIST OF FIGURES
FIGURE 1 NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN)
FIGURE 2 RESEARCH METHODOLOGY: NEUROMODULATION DEVICES GLOBAL MARKET
FIGURE 3 NEUROMODULATION DEVICES GLOBAL MARKET: TOP-DOWN AND BOTTOM-UP APPROACH
FIGURE 4 NEUROMODULATION DEVICES GLOBAL MARKET: FORECASTING MODEL
FIGURE 5 NEUROMODULATION DEVICES GLOBAL MARKET: MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 6 NEUROMODULATION DEVICES GLOBAL MARKET SEGMENTATION
FIGURE 7 MARKET DYNAMICS
FIGURE 8 NEUROMODULATION DEVICES GLOBAL MARKET: PORTER’S ANALYSIS
FIGURE 9 NEUROMODULATION DEVICES: SUPPLY CHAIN ANALYSIS
FIGURE 10 NEUROMODULATION DEVICES GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2019 (%)
FIGURE 11 SPINAL CORD STIMULATOR (SCS) GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2019 (%)
FIGURE 12 DEEP BRAIN STIMULATOR (DBS) GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYERS, 2019 (%)
FIGURE 13 CNS, PAIN MANAGEMENT AND GE & UROLOGY DEVICES MARKET PENETRATION IN U.S. NEUROMODULATION MARKET, 2019 (%)
FIGURE 14 NEUROMODULATION DEVICES GLOBAL MARKET SHARE, BY PRODUCT (2019 V/S 2026) (%)
FIGURE 15 NEUROMODULATION DEVICES GLOBAL MARKET SHARE, BY REGION (2019 V/S 2026) (%)
FIGURE 16 INTERNAL NEUROMODULATION DEVICES GLOBAL MARKET SHARE, BY PRODUCT TYPE (2019 V/S 2026) (%)
FIGURE 17 INTERNAL NEUROMODULATION DEVICES GLOBAL MARKET SHARE, BY REGION, (2019 V/S 2026) (%)
FIGURE 18 EXTERNAL NEUROMODULATION DEVICES GLOBAL MARKET SHARE, BY PRODUCT TYPE, (2019 V/S 2026) (%)
FIGURE 19 EXTERNAL NEUROMODULATION DEVICES GLOBAL MARKET SHARE, BY REGION, (2019 V/S 2026) (%)
FIGURE 20 NEUROMODULATION DEVICES GLOBAL MARKET SHARE, BY APPLICATION (2019 V/S 2026) (%)
FIGURE 21 PAIN MANAGEMENT GLOBAL MARKET SHARE, BY APPLICATION TYPE (2019 V/S 2026) (%)
FIGURE 22 PAIN MANAGEMENT GLOBAL MARKET SHARE, BY REGION, (2019 V/S 2026) (%)
FIGURE 23 CENTRAL NERVOUS SYSTEM (CNS) GLOBAL MARKET SHARE, BY APPLICATION TYPE, (2019 V/S 2026) (%)
FIGURE 24 CENTRAL NERVOUS SYSTEM (CNS) GLOBAL MARKET SHARE, BY REGION, (2019 V/S 2026) (%)
FIGURE 25 GASTROENTEROLOGY AND UROLOGY GLOBAL MARKET SHARE, BY APPLICATION TYPE, (2019 V/S 2026) (%)
FIGURE 26 GASTROENTEROLOGY AND UROLOGY GLOBAL MARKET SHARE, BY REGION, (2019 V/S 2026) (%)
FIGURE 27 NEUROMODULATION DEVICES GLOBAL MARKET SHARE, BY END-USERS (2019 V/S 2026) (%)
FIGURE 28 HOSPITALS AND AMBULATORY SURGERY CENTERS (ASC) GLOBAL MARKET SHARE, BY END-USERS, (2019 V/S 2026) (%)
FIGURE 29 CLINICS AND PHYSIOTHERAPY CENTERS GLOBAL MARKET SHARE, BY END-USERS, (2019 V/S 2026) (%)
FIGURE 30 ACADEMICS AND RESEARCH GLOBAL MARKET SHARE, BY END-USERS, (2019 V/S 2026) (%)
FIGURE 31 NEUROMODULATION DEVICES GLOBAL MARKET REVENUE, BY REGION (2018-2026) ($MN), CAGR (%)
FIGURE 32 NEUROMODULATION DEVICES GLOBAL MARKET SHARE, BY GEOGRAPHY (2019) (%)
FIGURE 33 NORTH AMERICA NEUROMODULATION DEVICES MARKET SHARE, BY PRODUCT, INTERNAL AND EXTERNAL NEUROMODULATION DEVICES BY PRODUCT TYPE (2019 V/S 2026) (%)
FIGURE 34 NORTH AMERICA NEUROMODULATION DEVICES MARKET SHARE, BY APPLICATION AND PAIN MANAGEMENT BY APPLICATION TYPE (2019) (%)
FIGURE 35 NORTH AMERICA CNS, GASTROENTEROLOGY AND UROLOGY MARKET SHARE, BY APPLICATION TYPE (2019 V/S 2026) (%)
FIGURE 36 NORTH AMERICA NEUROMODULATION DEVICES MARKET SHARE, BY END-USERS (2019 V/S 2026) (%)
FIGURE 37 NORTH AMERICA NEUROMODULATION DEVICES MARKET SHARE, BY COUNTRY (2019 V/S 2026) (%)
FIGURE 38 U.S. NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT, APPLICATION AND END-USERS (2019 V/S 2026) ($MN)
FIGURE 39 REST OF NORTH AMERICA NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT, APPLICATION AND END-USERS (2019 V/S 2026) ($MN)
FIGURE 40 EUROPE NEUROMODULATION DEVICES MARKET SHARE, BY PRODUCT, INTERNAL AND EXTERNAL NEUROMODULATION DEVICES BY PRODUCT TYPE (2019 V/S 2026) (%)
FIGURE 41 EUROPE NEUROMODULATION DEVICES MARKET SHARE, BY APPLICATION AND PAIN MANAGEMENT BY APPLICATION TYPE (2019) (%)
FIGURE 42 EUROPE CNS, GASTROENTEROLOGY AND UROLOGY MARKET SHARE, BY APPLICATION TYPE (2019 V/S 2026) (%)
FIGURE 43 EUROPE NEUROMODULATION DEVICES MARKET SHARE, BY END-USERS (2019 V/S 2026) (%)
FIGURE 44 EUROPE NEUROMODULATION DEVICES MARKET SHARE, BY COUNTRY (2019 V/S 2026) (%)
FIGURE 45 GERMANY NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT, APPLICATION AND END-USERS (2019 V/S 2026) ($MN)
FIGURE 46 FRANCE NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT, APPLICATION AND END-USERS (2019 V/S 2026) ($MN)
FIGURE 47 U.K. NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT, APPLICATION AND END-USERS (2019 V/S 2026) ($MN)
FIGURE 48 REST OF EUROPE NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT, APPLICATION AND END-USERS (2019 V/S 2026) ($MN)
FIGURE 49 APAC NEUROMODULATION DEVICES MARKET SHARE, BY PRODUCT, INTERNAL AND EXTERNAL NEUROMODULATION DEVICES BY PRODUCT TYPE (2019 V/S 2026) (%)
FIGURE 50 APAC NEUROMODULATION DEVICES MARKET SHARE, BY APPLICATION AND PAIN MANAGEMENT BY APPLICATION TYPE (2019) (%)
FIGURE 51 APAC CNS, GASTROENTEROLOGY AND UROLOGY MARKET SHARE, BY APPLICATION TYPE (2019 V/S 2026) (%)
FIGURE 52 APAC NEUROMODULATION DEVICES MARKET SHARE, BY END-USERS (2019 V/S 2026) (%)
FIGURE 53 APAC NEUROMODULATION DEVICES MARKET SHARE, BY COUNTRY (2019 V/S 2026) (%)
FIGURE 54 JAPAN NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT, APPLICATION AND END-USERS (2019 V/S 2026) ($MN)
FIGURE 55 CHINA NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT, APPLICATION AND END-USERS (2019 V/S 2026) ($MN)
FIGURE 56 INDIA NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT, APPLICATION AND END-USERS (2019 V/S 2026) ($MN)
FIGURE 57 REST OF APAC NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT, APPLICATION AND END-USERS (2019 V/S 2026) ($MN)
FIGURE 58 ROW NEUROMODULATION DEVICES MARKET SHARE, BY PRODUCT, INTERNAL AND EXTERNAL NEUROMODULATION DEVICES BY PRODUCT TYPE (2019 V/S 2026) (%)
FIGURE 59 ROW NEUROMODULATION DEVICES MARKET SHARE, BY APPLICATION AND PAIN MANAGEMENT BY APPLICATION TYPE (2019) (%)
FIGURE 60 ROW CNS, GASTROENTEROLOGY AND UROLOGY MARKET SHARE, BY APPLICATION TYPE (2019 V/S 2026) (%)
FIGURE 61 ROW NEUROMODULATION DEVICES MARKET SHARE, BY END-USERS (2019 V/S 2026) (%)
FIGURE 62 ROW NEUROMODULATION DEVICES MARKET SHARE, BY COUNTRY (2019 V/S 2026) (%)
FIGURE 63 BRAZIL NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT, APPLICATION AND END-USERS (2019 V/S 2026) ($MN)
FIGURE 64 REST OF LATAM NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT, APPLICATION AND END-USERS (2019 V/S 2026) ($MN)
FIGURE 65 MIDDLE EAST AND OTHERS NEUROMODULATION DEVICES MARKET REVENUE, BY PRODUCT, APPLICATION AND END-USERS (2019 V/S 2026) ($MN)
FIGURE 66 KEY GROWTH STRATEGIES, (2017-2019)
FIGURE 67 SWOT: ABBOTT LABORATORIES
FIGURE 68 SWOT: BEIJING PINS MEDICAL CO., LTD.
FIGURE 69 SWOT: BIONESS, INC.
FIGURE 70 SWOT: BOSTON SCIENTIFIC CORPORATION
FIGURE 71 SWOT: INSPIRE MEDICAL SYSTEM, INC.
FIGURE 72 SWOT: LABORIE MEDICAL TECHNOLOGY INC.
FIGURE 73 SWOT: LIVANOVA PLC
FIGURE 74 SWOT: MEDTRONIC PLC
FIGURE 75 SWOT: NEVRO CORPORATION
FIGURE 76 SWOT: NEUROPACE, INC.
FIGURE 77 SWOT: NUVECTRA CORPORATION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report